Literature DB >> 21196758

The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial.

Hui-Man Cheng1, Leih-Chin Chiang, Ya-Min Jan, Guang-Wei Chen, Tsai-Chung Li.   

Abstract

BACKGROUND: Severe and widespread atopic dermatitis often fails to respond adequately to topical steroids and oral antihistamines and requires immunomodulatory drugs which, although effective, have undesirable toxic effects.
METHODS: In this prospective, randomized, double-blind, placebo-controlled trial, 71 patients with severe intractable atopic dermatitis were given an 8-week treatment with oral Xiao-Feng-San (XFS; 47 patients) or placebo (24 patients). Total lesion score, erythema score, surface damage score, pruritus score and sleep score were measured at 4-week intervals.
RESULTS: Fifty-six patients completed both the treatment and follow-up periods. The decrease in the total lesion score in the treatment group at 8 weeks was significantly greater than that of the placebo group (79.7 ± 5.8% vs. 13.5 ± 7.64%; p < 0.001). There was also a statistically significant difference between the treatment and placebo groups with regard to erythema, surface damage, pruritus and sleep scores. The difference between the 2 groups was still significant for all outcome measures except the erythema score at the 12-week follow-up, 4 weeks after the 8-week treatment had ended. Patients reported no side effects from treatment, although some commented on the unpalatability of the medication.
CONCLUSION: Our study results suggest that the traditional Chinese herbal medicine XFS may be an alternative choice of therapy for severe, refractory, extensive and nonexudative atopic dermatitis.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 21196758     DOI: 10.1159/000318861

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  21 in total

Review 1.  Integrative medicine as adjunct therapy in the treatment of atopic dermatitis--the role of traditional Chinese medicine, dietary supplements, and other modalities.

Authors:  C DiNicola; A Kekevian; C Chang
Journal:  Clin Rev Allergy Immunol       Date:  2013-06       Impact factor: 8.667

Review 2.  Nonallergen-specific treatments for food allergy.

Authors:  Jay A Lieberman; Julie Wang
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-06

Review 3.  Management of itch in atopic dermatitis.

Authors:  Judith Hong; Joerg Buddenkotte; Timothy G Berger; Martin Steinhoff
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 4.  Therapeutic Benefits of Natural Ingredients for Atopic Dermatitis.

Authors:  George Man; Li-Zhi Hu; Peter M Elias; Mao-Qiang Man
Journal:  Chin J Integr Med       Date:  2017-09-01       Impact factor: 1.978

5.  Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms.

Authors:  Maihua Hou; Richard Sun; Melanie Hupe; Peggy L Kim; Kyungho Park; Debra Crumrine; Tzu-Kai Lin; Juan Luis Santiago; Theodora M Mauro; Peter M Elias; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2013-03       Impact factor: 3.960

6.  Evaluation of the efficacy and safety of a Chinese herbal formula (RCM-106) for atopic dermatitis: study protocol for a randomised, double-blind, placebo-controlled trial in children.

Authors:  Hsiewe Ying Tan; Anthony L Zhang; Charlie C Xue; Dacan Chen; Cliff Da Costa; George B Lenon
Journal:  BMJ Open       Date:  2013-12-30       Impact factor: 2.692

7.  Identifying chinese herbal medicine network for eczema: implications from a nationwide prescription database.

Authors:  Hsing-Yu Chen; Yi-Hsuan Lin; Sindy Hu; Sien-Hung Yang; Jiun-Liang Chen; Yu-Chun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-22       Impact factor: 2.629

8.  Danggui buxue tang inhibits 2,4-dinitrochlorobenzene: induced atopic dermatitis in mice.

Authors:  Li-Wen Fang; Chao-Chun Cheng; Tzann-Shun Hwang; Wen-Chung Huang; Chian-Jiun Liou; Wen-Chyuan Chen; Shu-Ju Wu
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-10       Impact factor: 2.629

9.  Topical apigenin alleviates cutaneous inflammation in murine models.

Authors:  Mao-Qiang Man; Melanie Hupe; Richard Sun; George Man; Theodora M Mauro; Peter M Elias
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-19       Impact factor: 2.629

10.  Effectiveness of keishibukuryogan on chronic-stage lichenification associated with atopic dermatitis.

Authors:  Megumi Mizawa; Teruhiko Makino; Hiroaki Hikiami; Yutaka Shimada; Tadamichi Shimizu
Journal:  ISRN Dermatol       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.